mammaprint (mp) microarray (Agendia BV)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Agendia BV mammaprint (mp) microarray

<t>MammaPrint</t> (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Mammaprint (Mp) Microarray, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/agendia+mammaprint+microarray/mammaprint++mp++microarray/pmc06742807-134-0-6
Average 90 stars, based on 1 article reviews

mammaprint (mp) microarray - by Bioz Stars, 2026-11

90/100 stars

Images

1) Product Images from "Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris"

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

Journal: Translational Oncology

doi: 10.1016/j.tranon.2019.08.008

MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Figure Legend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Techniques Used: Microarray, Comparison

Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

Figure Legend Snippet: Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

Techniques Used: Comparison, Microarray

Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 <xref ref-type=

∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D )." title="... ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

Techniques Used: Comparison, Microarray

MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Figure Legend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Techniques Used: Comparison, Microarray

Microarray:

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
Article Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites.

Review

mammaprint (mp) microarray (Agendia BV)

Structured Review

Images

1) Product Images from "Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris"

Related Articles

Microarray:

Comparison:

Next-Generation Sequencing:

Similar Products

Image Search Results